AquaBounty Technologies (AQB)
(Delayed Data from NSDQ)
$1.03 USD
+0.04 (3.54%)
Updated Aug 30, 2024 03:42 PM ET
After-Market: $1.05 +0.03 (2.44%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth C Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$1.03 USD
+0.04 (3.54%)
Updated Aug 30, 2024 03:42 PM ET
After-Market: $1.05 +0.03 (2.44%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth C Momentum F VGM
Zacks News
AquaBounty Technologies, Inc. (AQB) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
AquaBounty Technologies (AQB) delivered earnings and revenue surprises of -67.74% and 80%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
AquaBounty Technologies, Inc. (AQB) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
AquaBounty Technologies (AQB) delivered earnings and revenue surprises of -7.75% and 4.60%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Immunome, Inc. (IMNM) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Immunome (IMNM) delivered earnings and revenue surprises of 57.50% and 74.28%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Cara Therapeutics (CARA) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Cara (CARA) delivered earnings and revenue surprises of -47.37% and 5.11%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Arcus Biosciences, Inc. (RCUS) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Arcus Biosciences (RCUS) delivered earnings and revenue surprises of 94.85% and 454.49%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
AquaBounty Technologies, Inc. (AQB) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
AquaBounty Technologies, Inc. (AQB) delivered earnings and revenue surprises of 20% and 23.18%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
AquaBounty Technologies, Inc. (AQB) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
AquaBounty Technologies, Inc. (AQB) delivered earnings and revenue surprises of 11.11% and 12.30%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
AquaBounty Technologies, Inc. (AQB) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
AquaBounty Technologies, Inc. (AQB) delivered earnings and revenue surprises of 12.50% and 31.92%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Moderna (MRNA) Stock Jumps 8.6%: Will It Continue to Soar?
by Zacks Equity Research
Moderna (MRNA) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
AquaBounty Technologies, Inc. (AQB) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
AquaBounty Technologies, Inc. (AQB) delivered earnings and revenue surprises of 0% and 56.59%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
AquaBounty Technologies, Inc. (AQB) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
AquaBounty Technologies, Inc. (AQB) delivered earnings and revenue surprises of -42.86% and -40.37%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
AquaBounty Technologies, Inc. (AQB) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
by Zacks Equity Research
AquaBounty Technologies, Inc. (AQB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
AquaBounty Technologies, Inc. (AQB) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
AquaBounty Technologies, Inc. (AQB) delivered earnings and revenue surprises of -40.00% and -57.17%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Top ETF of December & Its Best Stocks
by Sweta Killa
We have highlighted the best ETF of December and its best performing stocks.
AquaBounty (AQB) Surges: Stock Moves 6.3% Higher
by Zacks Equity Research
AquaBounty (AQB) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.
AquaBounty Technologies, Inc. (AQB) May Report Negative Earnings: Know the Trend Ahead of Q2 Release
by Zacks Equity Research
AquaBounty Technologies, Inc. (AQB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
AquaBounty (AQB) Catches Eye: Stock Jumps 8.9%
by Zacks Equity Research
AquaBounty (AQB) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.
AquaBounty Technologies, Inc. (AQB) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
AquaBounty Technologies, Inc. (AQB) delivered earnings and revenue surprises of 15.38% and -30.00%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Will AquaBounty Technologies, Inc. (AQB) Report Negative Q1 Earnings? What You Should Know
by Zacks Equity Research
AquaBounty Technologies, Inc. (AQB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Amicus (FOLD) Provides Updates on AT-GAA for Pompe Disease
by Zacks Equity Research
Amicus (FOLD) announces updates on its investigational therapy, AT-GAA, for Pompe disease.
AquaBounty Technologies, Inc. (AQB) Upgraded to Strong Buy: What Does It Mean for the Stock?
by Zacks Equity Research
AquaBounty Technologies, Inc. (AQB) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
What Makes AquaBounty Technologies, Inc. (AQB) a New Strong Buy Stock
by Zacks Equity Research
AquaBounty Technologies, Inc. (AQB) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
AquaBounty Technologies, Inc. (AQB) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
AquaBounty Technologies, Inc. (AQB) delivered earnings and revenue surprises of 22.22% and -100.00%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Will AquaBounty Technologies, Inc. (AQB) Report Negative Q3 Earnings? What You Should Know
by Zacks Equity Research
AquaBounty Technologies, Inc. (AQB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Will AquaBounty Technologies, Inc. (AQB) Report Negative Q2 Earnings? What You Should Know
by Zacks Equity Research
AquaBounty Technologies, Inc. (AQB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.